The EPS miss and dilutive offering are significant negatives for a micro-cap biotech with no revenue. Monitor for further dilution risk and the Q4 2026 Japan PMDA submission catalyst. The stock may face continued selling pressure given the recent capital raise and weak quarterly results.
Price Chart
Executive Summary
BioCardia reported Q1 2026 EPS of -$0.21, missing the consensus estimate of -$0.18 by 16.7%. The company also disclosed a capital raise of 3,509,604 shares at an average price of $1.279, with net proceeds expected to extend cash runway into Q1 2027. The EPS miss and dilutive offering are negative signals for a micro-cap biotech with no revenue.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.21 missed consensus of -$0.18 by 16.7%
- Sold 3,509,604 shares at $1.279 average price on June 5, 2026
- Net proceeds expected to extend cash runway into Q1 2027
- No warrants issued in this capital raise
- Cash runway could extend further if outstanding warrants are exercised for cash
- Japan PMDA submission for CardiAMP HF expected in Q4 2026
Financial Impact
EPS miss of 16.7% combined with dilutive share issuance of ~3.5M shares at $1.279 (approx. $4.5M gross proceeds) for a $12M market cap company
Risk Factors
- Further dilution if outstanding warrants are exercised for cash
- Clinical trial failure or regulatory delay for CardiAMP HF
- Cash runway may be insufficient if PMDA submission is delayed
- No revenue stream to support operations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308021 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9000 (+0.28%) |
Oct 19, 2026 7d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9000 (−0.00%) |
Oct 7, 2026 19d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9000 (−17.43%) |
Oct 1, 2026 25d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Oct 1, 2026 25d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9000 (−18.18%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9000 (−15.09%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9000 (−5.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers